Dapansutrile(口服选择性NLRP3炎症小体抑制剂)治疗痛风发作:开放标签、剂量自适应、概念验证2a期试验
这项开放标签、概念验证2a期试验在荷兰门诊纳入34例经尿酸钠晶体证实的单关节痛风发作成人患者,按剂量自适应设计序贯接受100、300、1000或2000 mg/日口服dapansutrile共8天。主要终点为患者报告的目标关节疼痛从基线至第3天和第7天的变化(符合方案人群),安全性在意向治疗人群评估。结果显示各剂量组第3天和第7天疼痛均较基线下降,安全性总体可接受,但研究样本量小、开放标签,需后续研究确认临床潜力。
要点
- 各剂量组第3天和第7天目标关节疼痛均较基线下降,部分剂量组差异有统计学意义。
- 研究为开放标签、小样本概念验证试验,结论需后续研究确认。
核心结论
- Dapansutrile作为选择性NLRP3炎症小体抑制剂,在本研究中显示出可接受的安全性及降低目标关节疼痛的疗效。
研究设计与样本
- 开放标签、概念验证2a期试验,在荷兰门诊纳入34例经尿酸钠晶体证实的单关节痛风发作成人患者(18-80岁)。
- 采用剂量自适应设计序贯分配至100、300、1000或2000 mg/日口服dapansutrile共8天。
- 共同主要终点为患者报告的目标关节疼痛从基线至第3天和第7天的变化,在符合方案人群(29例)评估;安全性在意向治疗人群(34例)评估。
主要发现
- 研究期间发生2例严重不良事件:第3天因痛风发作加重住院,以及末次给药后18天因冠状动脉狭窄住院;均为中等严重程度且与研究药物无关。
临床怎么用
- 本研究为早期概念验证试验,dapansutrile尚未获批用于痛风发作,临床决策不应据此常规使用。
- 口服NLRP3炎症小体抑制剂靶向IL-1β通路,为痛风发作抗炎治疗提供了待验证的新方向。
局限性
- 开放标签设计,缺乏安慰剂对照,可能引入偏倚。
- 样本量小(符合方案29例,意向治疗34例),各剂量组仅6-8例。
- 为概念验证2a期试验,疗效与安全性需更大规模对照研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gout flares are driven by interleukin (IL)-1β. Dapansutrile inhibits the NLRP3 inflammasome and subsequent activation of IL-1β. In this study we aimed to investigate the safety and efficacy of orally administered dapansutrile in patients with a gout flare. METHODS: In this open-label, proof-of-concept, phase 2a trial, adult patients (aged 18-80 years) with a monoarticular monosodium urate crystal-proven gout flare were enrolled at an outpatient clinic in the Netherlands and sequentially assigned using a dose-adaptive design to receive 100 mg/day, 300 mg/day, 1000 mg/day, or 2000 mg/day oral dapansutrile for 8 days. The coprimary outcomes were change in patient-reported target joint pain from baseline to day 3 and from baseline to day 7, assessed in the per-protocol population (all patients who received at least 80% of the study drug and had no major protocol deviations). Safety was assessed in the intention-to-treat population. This trial is registered with the EU Clinical Trials Register, EudraCT 2016-000943-14, and is completed. FINDINGS: Between May 18, 2017, and Jan 21, 2019, 144 patients were assessed for eligibility, of whom 34 were enrolled and 29 were included in the per-protocol population (three patients were excluded due to receiving <80% of study drug and two had major protocol deviations): eight patients received 100 mg/day, seven received 300 mg/day, six received 1000 mg/day, and eight received 2000 mg/day. Between baseline and day 3, there was a mean reduction in patient-reported target joint pain of 52·4% (SD 32·94; p=0∙016) for the 100 mg/day group, 68·4% (34·29; p=0∙016) for the 300 mg/day group, 55·8% (44·90; p=0∙063) for the 1000 mg/day group, and 57·6% (38·72; p=0∙016) for the 2000 mg/day group. At day 7, there was a mean reduction of 82·1% (22·68; p=0∙031) for the 100 mg/day group, 84·2% (16·33; p=0∙016) for the 300 mg/day group, 68·9% (34·89; p=0∙031) for the 1000 mg/day group, and 83·9% (15·44; p=0∙008) for the 2000 mg/day group, compared to baseline. 25 (73·5%) of 34 patients reported a total of 45 treatment-emergent adverse events, most of which were metabolism and nutrition disorders (17 [37·8%]) and gastrointestinal disorders (ten [22·2%]). Two serious adverse events occurred during the study, admission to hospital because of worsening of gout flare at day 3, and admission to hospital because of coronary stenosis 18 days after the patient received their last dose; these were considered moderate in severity and unrelated to the study drug. INTERPRETATION: Dapansutrile is a specific NLRP3 inflammasome inhibitor with a satisfactory safety profile and efficacy in the reduction of target joint pain in this study. Future studies are needed to confirm the clinical potential of dapansutrile.
引用
- Klück V, Jansen TLTA, Janssen M, et al. Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. Lancet Rheumatol. 2020. PMID: 33005902. doi:10.1016/s2665-9913(20)30065-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。